Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Idarubicin HCl PFS: Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

Idarubicin HCl PFS - General Information

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem]

 

Pharmacology of Idarubicin HCl PFS

Idarubicin HCl PFS is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin HCl PFS may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin HCl PFS possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

 

Idarubicin HCl PFS for patients

 

Idarubicin HCl PFS Interactions

No Information Provided.

 

Idarubicin HCl PFS Contraindications

No Information Provided.

 

Additional information about Idarubicin HCl PFS

Idarubicin HCl PFS Indication: For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. Mechanism Of Action: Idarubicin HCl PFS has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin HCl PFS forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Idarubicin Synonyms: Idarubicin Hcl; Idarubicin Hydrochloride; Idarubicina [Inn-Spanish]; Idarubicine [Inn-French]; Idarubicinum [Inn-Latin] Drug Category: Antibiotics; Antineoplastic Agents Drug Type: Small Molecule; Approved Other Brand Names containing Idarubicin: Idamycin; Idamycin PFS; Idarubicin Aglycone; Idarubicin HCl PFS; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: 97% Biotransformation: Not Available Half Life: 22 hours Dosage Forms of Idarubicin HCl PFS: Powder, for solution Intravenous Chemical IUPAC Name: (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical Formula: C26H27NO9 Idarubicin on Wikipedia: https://en.wikipedia.org/wiki/Idarubicin Organisms Affected: Humans and other mammals; Bacteria